regulatory approval

News

After FDA says no, Bayer bags EU nod for twice-yearly Eylea

Bayer has been given a leg up in the competitive market for VEGF therapies used to treat eye diseases with a new EU approval for Eylea 8mg.

News

PTC Therapeutics' chief executive Matthew Klein.

Germany will be first launch for PTC's phenylketonuria drug

PTC Therapeutics' treatment for the rare disease PKU, Sephience, will launch in its first market next month after getting EU approval.

News

AZ, Daiichi get Datroway nod in lung cancer on second try

AZ and Daiichi Sankyo have claimed FDA approval for Datroway in lung cancer after switching indications for the TROP2-directed drug.

News

Dupixent is first FDA-approved drug for rare skin disease

The long list of therapeutic uses for Sanofi and Regeneron's Dupixent has been lengthened by an FDA approval for rare skin disease bullous pemphigoid.

News

Gilead's twice-yearly PrEP drug is cleared by FDA

Gilead has FDA approval for a twice-yearly PrEP drug, but could proposed cuts to US funding for HIV prevention programmes hinder its take-up?

News

FDA green lights CSL's once-monthly HAE drug Andembry

CSL has won FDA approval for Andembry, its once-monthly subcutaneous drug to prevent hereditary angioedema (HAE) attacks.

After FDA says no, Bayer bags EU nod for twice-yearly Eylea

Germany will be first launch for PTC's phenylketonuria drug

AZ, Daiichi get Datroway nod in lung cancer on second try

Dupixent is first FDA-approved drug for rare skin disease

Gilead's twice-yearly PrEP drug is cleared by FDA

FDA green lights CSL's once-monthly HAE drug Andembry

Repligen builds in cell therapy with $1.5bn BioLife takeover

Discover a new era of healthcare panel engagement: Grounded ...

regulatory approval

Editor's Picks